Antibody-Based Treatment Approaches in Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33730360/
Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel t ...
-
Mark FeslerApril 10, 2021There are many more surface targets that have been identified in myeloma beyond cd38, slamf1, and bcma which is extremely exciting for the future of myeloma care